TrialFuture oncology (London, England)2025

Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patients.

Rana R McKay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.